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Abstract
People with bipolar disorder frequently experience persistent residual symptoms, problems in psychosocial functioning, 
cognitive impairment, and poor quality of life. In the last decade, the treatment target in clinical and research settings has 
focused not only on clinical remission, but also on functional recovery and, more lately, in personal recovery, taking into 
account patients’ well-being and quality of life. Hence, the trend in psychiatry and psychology is to treat bipolar disorder in 
an integrative and holistic manner. This literature review offers an overview regarding psychosocial functioning in bipolar 
disorder. First, a brief summary is provided regarding the definition of psychosocial functioning and the tools to measure it. 
Then, the most reported variables influencing the functional outcome in patients with bipolar disorder are listed. Thereafter, 
we include a section discussing therapies with proven efficacy at enhancing functional outcomes. Other possible therapies 
that could be useful to prevent functional decline and improve functioning are presented in another section. Finally, in the 
last part of this review, different interventions directed to improve patients’ well-being, quality of life, and personal recovery 
are briefly described.
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Introduction
Bipolar disorder (BD) is a recurrent and chronic disorder char-
acterized by fluctuations in mood state and energy that af-
fects around 2.4% of the global population (Merikangas et al., 
2011). As a lifelong and recurrent illness, BD is associated with 
functional decline, cognitive impairment, and a reduction in 
quality of life (QoL) (Martínez-Arán et al., 2004; Michalak et al., 
2005; Bonnín et al., 2012). Given the complexity of this illness 
and its consequences, researchers and clinicians are not only 
focused on clinical remission but also functional recovery 
and, more lately, well-being too (Vieta and Torrent, 2016). This 
emergent paradigm includes not only symptom recovery but 
also return to normal functioning and attainment of a mean-
ingful life. In fact, in 1988, Dion and colleagues already pointed 
out that factors other than symptoms were related to func-
tioning of patients with BD and that treatment should target 
symptom amelioration as well as reduce a patient’s disability 
(Dion et al., 1988). It is known that even after the first manic 
episode, only 1 out of 3 patients regains psychosocial func-
tioning at 1 year follow-up (Tohen et al., 2000), suggesting that 
functional outcomes in BD are undoubtedly impaired from the 
very beginning and should become a priority in therapeutic 
interventions.
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In the last decade, many efforts have been made to improve 
functioning and well-being in BD; hence, this review aims at pro-
viding a brief overview of both issues. First, the definition and 
how to measure functioning is discussed. Then, a brief review 
of the variables influencing psychosocial functioning is per-
formed. The following sections present some treatments that 
have proven to be effective at enhancing functional outcomes 
and other promising treatments that might also be useful at 
targeting functional impairment and prevent functional de-
cline. Finally, a brief overview of therapies directed to improve 
well-being and QoL is also presented.
Definition of Psychosocial Functioning and 
How to Measure It
Despite the importance of psychosocial functioning in BD there 
is not a clear consensus regarding its definition. In the Task 
Force for the International Society for Bipolar Disorders con-
ducted by Tohen and colleagues in 2009, different definitions of 
psychosocial functioning were examined but without reaching 
a consensus. The experts highlighted the definition provided 
by the International Classification of Functioning, Disability 
and Health (ICF) in which functioning comprises 3 different 
components: body structures and functions; activities and par-
ticipation; and personal environmental factors. Moreover, the 
authors of these guidelines underlined that this construct was 
complex to measure and that besides the ICF, the Functioning 
Assessment Short Thest (FAST) scale (Rosa et  al., 2007) might 
also constitute a good approach to measure functioning (Tohen 
et al., 2009). Before these guidelines, there were other attempts 
to define psychosocial functioning. For instance, in 2000, Zarate 
and colleagues suggested the assessment of psychosocial func-
tioning should involve different behavioral domains such as the 
individuals’ ability to function socially or occupationally, to live 
independently, and to engage in a romantic life, with functional 
recovery typically being defined as the restoration of normal 
role functioning in the domains under scrutiny (Zarate et  al., 
2000). This definition represented a breakthrough in the field be-
cause in that moment, psychosocial functioning was measured 
by means of the Global Assessment Functioning Scale (GAF), 
endorsed by several consecutive editions of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM). The GAF pro-
vides 1 single score without differentiating between the behav-
ioral domains pointed by Zarate and colleagues. Despite all, the 
GAF is still the most commonly used clinician rating scale to 
measure disability, at least in the United States (Von Korff et al., 
2011). In 2007, Rosa and colleagues developed a tool to measure 
functioning, the already mentioned FAST scale. It was specific-
ally created to measure the most common difficulties experi-
enced by patients with BD. The rationale behind this scale is in 
line with the definition of functioning proposed by Zarate and 
colleagues in 2000, mostly focused on the assessment of dif-
ferent behavioral domains. More specifically, the FAST targets 
the following areas: autonomy, occupational functioning, cog-
nitive functioning, financial issues, interpersonal functioning, 
and leisure time. In this regard, the FAST represented several 
advantages over the GAF, mainly that it assesses different be-
havioral domains, it does not rate the symptomatology, and it 
is specific for BD.
Currently, the DSM-5 no longer encourages the use of the 
GAF. Instead, the use of the World Health Organization Disability 
Assessment Schedule 2.0 (WHODAS 2.0) (Üstün et  al., 2010) is 
recommended. The WHODAS 2.0 allows the assessment of 
functioning and disability irrespective of diagnosis; that is, it can 
reflect difficulties due to any medical or psychiatric illness. In 
contrast, both the GAF and the FAST are limited to the impact of 
the psychiatric disease on functioning, excluding the medical or 
environmental limitations. The GAF, FAST, WHODAS 2.0, or ICF 
core sets specific for BD (Vieta et al., 2007; Ayuso-Mateos et al., 
2013) are clinical tools, either rater administered (GAF, FAST, 
ICF core sets) or self-administered (WHODAS 2.0), but other ap-
proaches exist. For instance, the UCSD Performance-based skills 
Assessment (UPSA) (Patterson et al., 2001) is based on task per-
formance and measures functional capacity, assessing the skills 
involved in community tasks such as comprehension and plan-
ning, finance, communication, mobility, and house manage-
ment. Figure 1 represents an overview of some different scales 
available to measure functioning in BD during the last 40 years, 
starting in 1980, when the GAF was first endorsed by the DSM-III 
until the present.
The scales presented in Figure 1 are just a little part of the big 
picture of the measurement of psychosocial functioning in BD. 
Nevertheless, it fairly represents the great variability that exists. 
It is likely that the way the researcher or clinician defines psy-
chosocial functioning will determine the tool to measure it, but 
the reverse is true as well: the use of one tool or another implies 
how the concept of psychosocial functioning is understood. To 
overcome this bias, it would be ideal that psychosocial func-
tioning could be measured taking into account 3 different per-
spectives: (1) a subjective view using a self-administered scale, 
such as the Sheehan Disability Scale for BD (SDS) (Arbuckle 
et al., 2009) or the WHODAS 2.0; (2) a semi-objective scale, using 
the FAST, GAF, or LIFE-RIFT (Leon et al., 1999), which are inter-
viewer rated based on patients’ answers; and finally (3) an ob-
jective scale, like the UPSA, which is performance based and 
measures functional capacity. Combining these 3 different ap-
proaches might help to disentangle all the variables associated 
with functional impairment observed in BD.
Variables Influencing Functional Outcome 
in BD
Many variables have been associated with functional outcome in 
BD, including demographic, clinical, and neurocognitive factors. 
The brief summary presented below includes findings reported 
in some studies that use different scales, including the GAF, 
FAST, The Multidimensional Scale of Independent Functioning 
(Berns et al., 2007), and SDS among others. As mentioned above, 
there is a great variability not only in the assessment of func-
tioning but also in the variables reported to influencing it. 
Despite this, the next paragraphs are useful to reveal the mag-
nitude of the complex construct that researchers and clinicians 
are trying to predict.
Concerning the sociodemographic factors, it seems that 
male patients (Tohen et al., 1990; Sanchez-Moreno et al., 2018) as 
well as older patients (Sanchez-Moreno et al., 2018) show poorer 
functional outcomes. On the other hand, being married could 
represent a protective factor against functional impairment 
(Kupfer et  al., 2002; Wingo et  al., 2010). Higher socioeconomic 
status, based on education and employment, has also been 
associated with better functional outcomes (Keck et  al., 1998; 
Wingo et al., 2010).
Regarding the clinical variables, the presence of subsyndromal 
depressive symptoms has been consistently reported as 
the strongest factor associated with functional impairment 
(Tohen et  al., 1990; Bonnín et  al., 2010, 2012; Gitlin et  al., 2011; 
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Gutiérrez-Rojas et al., 2011; Reinares et al., 2013; Samalin et al., 
2016; Murru et al., 2018). Other clinical variables include history of 
psychosis, episode density, poor sleep quality, and longer illness 
duration (Huxley and Baldessarini, 2007; Sanchez-Moreno et al., 
2009a, 2010; Reinares et al., 2013; Etain et al., 2017; Murru et al., 
2018). Psychiatric comorbidity, particularly with substance use 
disorder (e.g., cannabis, alcohol) and personality disorders, can 
also negatively influence functional outcomes in patients with 
BD (Sánchez-Moreno et al., 2009b; Leen et al., 2013; Icick et al., 
2017; Kizilkurt et al., 2018; Williams and Simms, 2018).
Finally, regarding neurocognitive variables, verbal memory 
has been found to be a good predictor of functional outcome in 
several studies (Martinez-Aran et al., 2007; Bonnín et al., 2010, 
2014, Torres et  al., 2011; Jiménez-López et  al., 2018), However, 
variables related to other neurocognitive areas have also been 
reported, including executive functions, processing speed, and 
attention (Jaeger et al., 2007; Mur et al., 2009; Wingo et al., 2010). 
It might be hypothesized that the neurocognitive variables 
influencing functional outcome in BD may vary depending on 
illness progression. For instance, patients in early stages of the 
disease seem to present a more selective profile of cognitive im-
pairment, with some domains capable of improving 1 year after 
the first manic episode, including improvements in processing 
speed and executive functions (Torres et al., 2014). In this line, 
at least 2 studies have found that first-episode patients who 
did not relapse during 1-year follow-up could improve their 
neurocognitive functioning (Kozicky et al., 2014; Demmo et al., 
2018); hence, preserving neurocognition from the very begin-
ning of the illness might guarantee better functional outcomes.
Restoring Psychosocial Functioning: 
Therapies That Have Improved Functional 
Outcome
Pharmacological Interventions
Research on pharmacological and nonpharmacological treat-
ments to restore functioning in BD is still immature. As 
previously mentioned, the link between functional outcomes 
and neurocognition is well recognized, which is why in recent 
years many efforts have improved cognition, including both 
pharmacological and psychological treatments. In fact, new 
trends in pharmacological treatments include focusing on re-
storing cognitive functioning rather than psychosocial func-
tioning. Among the most promising medical treatments to 
improve cognition in BD are mifepristone (Watson et al., 2012), 
lurasidone (Yatham et al., 2017), and erythropoietin (Miskowiak 
et  al., 2014, 2015). Given the link between neurocognition and 
psychosocial functioning, it is likely that the efforts directed to 
improve neurocognition will also improve functional outcome; 
however, so far, no studies on pharmacological treatments have 
addressed both issues at the same time. It is worth mentioning 
that the methodological recommendations for cognition trials 
by the Cognition Task Force from the International Society 
for Bipolar Disorders encourage the inclusion of a functional 
measure as a key secondary outcome (Miskowiak et al., 2017). 
In this regard, a tool to measure functional improvement that 
allows the researchers and clinicians to classify patients into 
different categories of functional performance could be useful 
to assess the efficacy of these treatments (Bonnín et al., 2018a).
Psychological Therapies
In contrast to the area of pharmacological treatments, in the 
field of psychological interventions several efforts have been 
made lately to design therapies to restore psychosocial func-
tioning in BD. The first attempt was an open trial using a pro-
gram named Cognitive Rehabilitation (Deckersbach et al., 2010). 
The authors included a total of 18 patients with subsyndromal 
depressive symptoms and after 14 session of cognitive rehabili-
tation, patients improved cognitive performance and functional 
outcome. More interestingly, the findings showed that changes 
in executive function accounted, in part, for the improvements 
in occupational functioning. The first randomized controlled 
trial (RCT) implementing a similar therapy was conducted in 
2013 by Torrent and colleagues (Torrent et  al., 2013). The ef-
ficacy of functional remediation (FR) was proved in terms of 
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Figure 1. Timeline representing some scales to measure psychosocial functioning in bipolar disorder over the last 40 years. FAST, Functioning Assessment Short Test; 
GAF, Global Assessment of Functioning Scale; ICF, International Classification of Functioning, Disability, and Health; LIFE-RIFT, The Range of Impaired Functioning Tool; 
SDS, Sheehan Disability Scale; MSIF, Multidimensional Scale of Independent Functioning; UPSA, the UCSD Performance-based skills Assessment; WHODAS 2.0, World 
Health Organization Disability Assessment Schedule.
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improving functional outcomes in euthymic patients with mod-
erate to severe functional impairment at baseline. Moreover, 
improvement in psychosocial functioning was maintained after 
6 months’ follow-up (Bonnin et al., 2016). However, the impact 
of the intervention was low in terms of cognition. Contrary to 
others therapies labeled as “cognitive remediation,” FR is spe-
cially centered on functional recovery, focusing on the training 
of neurocognitive skills that are useful for daily functioning. 
Hence, this approach might be suitable especially for patients 
in late stages of the illness and who present moderate to severe 
functional impairment. Another preliminary study conducted 
in the Netherlands included 12 patients and replicated the 
positive results in functional outcome after receiving a shorter 
FR program (Zyto et  al., 2016). However, not all the interven-
tions targeting cognitive rehabilitation were found to improve 
functional outcome. For instance, another RCT conducted by 
Demant and colleagues (2015) found no improvement on either 
cognition or functional outcome after a 12-week interven-
tion. It is worth mentioning that these negative results might 
be explained by some methodological limitations of the trial, 
including the length of the intervention (too short) or the fact 
that patients were subsyndromic at study enrolment. Another 
study leaded by Lewandowski and colleagues (2017) assessed 
the efficacy of an internet-based cognitive remediation program 
in patients with BD compared with an active control group both 
in neurocognition and community functioning. After treatment, 
patients who received the internet-based program improved 
cognitive performance in processing speed, visual learning 
and memory domains, and the composite score. These results 
were maintained over 6  months after finishing the interven-
tion; however, the intervention was not associated with change 
in community functioning, although cognitive change was as-
sociated with functional change across the sample. There are 
other ongoing trials targeting cognition including action-based 
cognitive remediation programs in which computerized training 
is combined with practical in-session activities and cognitively 
challenging tasks between sessions. This novel approach may 
have greater effect at enhancing functional outcomes than trad-
itional cognitive remediation programs (Bowie et al., 2017; Ott 
et al., 2018).
It is difficult to measure the power of these current ap-
proaches in changing functioning, since very few studies have 
used psychosocial functioning as a primary outcome. In this re-
gard, meta-analyses providing these data are urgently needed.
How to Prevent Functional Decline: 
Promising Therapies
So far, there is no strong evidence regarding the prevention of 
functional decline in BD. The following section includes some 
targets and treatments that could address this issue and de-
serve to be further explored.
Addressing Subthreshold Depressive Symptoms
A considerable portion of the patients with BD (more than 50%) 
experience inter-episode residual depressive symptoms (De 
Dios et al., 2010; Gitlin et al., 1995), preventing them from living 
to the fullest. In this regard, subthreshold depressive symptoms 
together with neurocognitive impairment might be one of the 
strongest predictors of functional outcome (Bonnín et al., 2010, 
2012, 2014; Reinares et al., 2013; Martinez-Aran and Vieta, 2015; 
Samalin et al., 2017). However, the relationship between func-
tional outcome and subthreshold depressive symptoms might 
not be linear and unidirectional; instead, they seem to influ-
ence one another (Gitlin and Miklowitz, 2017; Weinstock and 
Miller, 2008). Besides the implications in functional outcome, 
residual depressive symptoms are also a major cause of relapse 
(Vieta and Garriga, 2016; Radua et  al., 2017), consequently af-
fecting psychosocial functioning and QoL (Bonnín et  al., 2012; 
Xiang et al., 2014). The treatment of residual depressive symp-
toms during euthymia is an unmet need, but fortunately, clin-
ical research has begun to investigate how to tackle them. One 
recent RCT proved that adjunctive extended-release quetiapine 
at a dose of 300 mg daily was significantly more effective than 
placebo in the treatment of subthreshold depressive symptoms 
(Garriga et  al., 2017), but no significant improvement was de-
tected in functional outcome. One possible explanation is that 
the sample size was not powered enough to detect significant 
changes in this secondary outcome.
Regarding psychological interventions, a limited number 
of therapies have addressed subthreshold depressive symp-
toms as a primary outcome. To the best of our knowledge, 
only one pilot RCT study assessed the effect of Eye Movement 
Desensitization and Reprocessing therapy on this type of symp-
tomatology. Specifically, patients in the treatment group showed 
a statistically significant improvement in depressive and hypo-
manic symptoms when compared with treatment as usual at 
12-month follow-up; however, psychosocial functioning was 
not assessed (Novo et  al., 2014). Another multicenter study of 
Eye Movement Desensitization and Reprocessing with a bigger 
sample is underway with the objective to reduce symptoms 
and relapses and improve psychosocial functioning (Moreno-
Alcázar et al., 2017). Regarding FR, secondary analyses showed 
that patients with subsyndromal symptoms could also improve 
psychosocial functioning after the therapy (Sanchez-Moreno 
et al., 2017).
Other therapies include an approach testing the long-term 
efficacy of an intervention that combined cognitive behavior 
therapy (CBT) and psychoeducation, which has also been 
described to be effective in terms of symptoms and social-
occupational functioning improvement (González-Isasi et  al., 
2014). Positive results in social functioning were also found with 
CBT (Lam et al., 2003). Inder and colleagues (2015) randomized 
a group of patients with BD to Interpersonal and Social Rhythm 
Therapy or specialist supportive care, and both groups improved 
in depressive/manic symptoms and social functioning. Finally, 
an intensive psychotherapy (family-focused treatment [FFT], 
Interpersonal and Social Rhythm Therapy, or CBT) in patients 
with BD during an acute depressive episode also showed bene-
ficial functional outcomes (Miklowitz et al., 2007a). Finally, posi-
tive results have also been reported on anxious and depressive 
symptoms using mindfulness-based cognitive therapy (Williams 
et al., 2008; Ives-Delipery et al., 2013; Perich et al., 2013).
Although more research is needed, it might be hypothesized 
that treating subthreshold depressive symptoms could be an in-
direct pathway to improve psychosocial functioning.
Enhancing Cognitive Reserve
Cognitive reserve (CR) is the capacity of the adult brain to en-
dure neuropathology, minimizing clinical manifestations and 
allowing a successful accomplishment of cognitive tasks (Stern, 
2009). Genetics determine, to some extent, CR; however, environ-
mental factors such as an active lifestyle, education, and brain 
stimulation (mental activities) can also influence it. In BD the 
most common ways to measure CR include years of education, 
premorbid Intelligence Quotient, and leisure activities. So far, 
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no interventions have tested whether improving CR enhances 
functioning, but some studies suggest that CR is a good pre-
dictor of both cognitive and psychosocial outcome in euthymic 
patients with BD (Anaya et al., 2012; Forcada et al., 2015). Further, 
it could also play an important role in patients with first psych-
otic episode since CR has shown to predict psychosocial func-
tioning 2  years after the first episode (Amoretti et  al., 2016). 
Hence, given the role of CR both in chronic patients and at early 
stages, this might constitute an area to explore and enhance to 
prevent functional decline (Vieta, 2015). In this regard, there is 
another ongoing trial by Torrent and colleagues (NCT03722082) 
that aims to enhance CR in child, adolescent, and young adult 
offspring of patients diagnosed with schizophrenia or BD; how-
ever, so far, no preliminary results are available. 
Diet and Physical Exercise
Nutrition and physical exercise play a critical role in both the 
mental and physical health of patients with BD. Physical in-
activity and poor diet habits can contribute to obesity, diabetes, 
hypertension, and dyslipidemia, which, in turn, increase the risk 
for cardiovascular disease (Soreca et al., 2008). At any rate, these 
risk factors should be targeted since it has been shown that 
obesity can also impact cognitive functioning (Mora et al., 2017), 
and in turn, cognitive impairment could be a predictor of weight 
gain (Bond et  al., 2017). Hence, it seems that weight increase 
and cognitive impairment can influence one another. Moreover, 
another study has found that increased body mass index (BMI) 
was associated with a more chronic course of the disease, longer 
duration of illness, and lower psychosocial functioning (Calkin 
et al., 2009). In line with this, Bond and colleagues (2010) found 
that those patients who suffered a clinically significant weight 
gain (defined as gaining ≥7% of baseline weight over 12 months) 
had significantly poorer functional outcomes at 12-month 
follow-up, and, interestingly, functional impairment was inde-
pendent from current mood symptoms.
Poor dietary habits and a sedentary lifestyle can increase 
physical and psychiatric morbidity, worsen psychosocial and 
cognitive functioning, and predict a poor pharmacological re-
sponse. That is why clinicians treating individuals with BD face 
a dual challenge of treating not only patients’ brains but also 
their bodies. Interventions targeting healthy habits (including 
nutrition and exercise) are expected to benefit patients with 
BD. One RCT examined the effects of a 20-week CBT interven-
tion (NEW tx) for BD consisting of 3 modules: nutrition, exer-
cise, and wellness (Sylvia et al., 2013); patients who underwent 
the treatment showed improvements in nutritional habits, 
exercise, depressive symptoms, and overall functioning. Hence, 
this study provides preliminary evidence that improving nutri-
tion and promoting an active lifestyle is associated with func-
tional improvement and mood symptoms in patients with BD. 
Another previous study showed the efficacy of an intervention 
on healthy lifestyle, nutrition, and physical exercise on muscle 
mass index, particularly in women (Gillhoff et al., 2010). These 
lifestyle interventions are promising since they demonstrate 
that people with BD can engage and be successful in these types 
of therapies. Therapeutic mechanisms of action are still un-
known but might include different pathways, for example, by 
reducing morbidity (i.e., depressive symptoms), which in turn 
would improve functional outcome (Ernst et  al., 2006), or by 
enhancing treatment effects, including the synergistic effects 
of exercise in combination with other treatments. For instance, 
in schizophrenia there is some preliminary evidence suggesting 
that cognitive remediation efficacy can be enhanced by aerobic 
exercise-induced BDNF upregulation (Nuechterlein et al., 2016; 
Campos et al., 2017).
Multicomponent Programs
One advantage of this type of intervention is to tackle different 
areas to be improved at the same time, hence, allowing a holistic 
treatment of patients, taking into account not only education on 
the illness but also how to improve healthy lifestyles and func-
tional outcomes. Following the premise that no single psychosocial 
intervention might be sufficient to address the morbidity, the func-
tional impairment and the consequences associated with severe 
mental illnesses (Kern et al., 2009), multicomponent programs, and 
care packages are being developed for patients with BD.
An example of this kind of treatment that has proven to be 
effective in BD is the Integrated Risk Reduction Intervention de-
veloped by Frank and colleagues (2015). More specifically, this 
program consists of 17 sessions grouped in different modules, 
including psychoeducation, training to improve sleep/wake 
patterns and social rhythm regularity, nutrition, physical ac-
tivity, and healthy habits (smoking cessation). Results from this 
study showed that patients who followed the intervention sig-
nificantly reduce their BMI. Moreover, 3 variables (C-reactive 
protein, total cholesterol, and instability of total sleep time) con-
tributed to a combined moderator of faster decrease in BMI with 
Integrated Risk Reduction Intervention treatment.
Recently, the Bipolar Disorder and Depression Unit in Barcelona 
has developed an integrative approach consisting of therapeutic 
components of broader programs that the Barcelona Bipolar 
Disorders Program had previously developed and whose effect-
iveness had been proven separately, such as psychoeducation for 
patients (Colom et al., 2003), psychoeducation for family mem-
bers (Reinares et al., 2008), and FR (Torrent et al., 2013). In addition, 
an important emphasis is given to the promotion of a healthy 
lifestyle, and a module focused on mindfulness-based cogni-
tive therapy has also been included. Therefore, some contents of 
psychoeducation for patients have been combined with a session 
for family members and complemented with aspects related to 
health promotion, mindfulness training, and strategies for cog-
nitive and functional enhancement, always as adjunctive to 
pharmacological treatment. This integrative approach combines 
the main components of different treatments to cover broader 
therapeutic objectives, to improve the prognosis of the disease in 
both clinical and functional aspects, as well as the well-being and 
QoL of those who suffer from BD (Reinares, Martínez-Arán and 
Vieta, in press). Due to the characteristics of the intervention (12 
sessions of 90 minutes each), in case it shows its efficacy, it could 
be easily implemented in routine clinical care.
Personal Recovery: Well-being and QoL 
Subjective assessments and patient-reported outcomes are gaining 
ground in the field of BD (Morton et al., 2017; Bonnín et al., 2018b). 
As in psychosocial functioning, the problem with subjective meas-
ures is the variability in the definitions and in the instruments to 
assess the subjective experience of these patients (Morton et al., 
2017). It is common that terms such as QoL, well-being or life satis-
faction are used as synonyms and interchangeable terms (Morton 
et al., 2017). Moreover, the current lack of consensus between these 
construct definitions add uncertainty and complication to select 
an appropriate instrument to measure this dimension. Despite 
all, the subjective experience should always be taken into account 
since it can also impact on the course of the illness. Some studies 
indicate that the improvement in well-being provides a protective 
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effect against recurrence (Keyes et al., 2010), and it has also been 
found that low levels in QoL are associated with an increase in oxi-
dative stress (Nunes et al., 2018). For this reason, it is important to 
evaluate not only objective outcomes (symptoms and functioning) 
but also to assess patients’ subjective experience, since they can 
provide valuable information and might be an essential part to en-
sure better outcomes in BD.
Pharmacological Interventions
Rajagopalan et  al. (2016) tested the effects of lurasidone as 
monotherapy or as adjunctive to lithium/valproate on health-
related QoL (HRQoL). They found that patients in both condi-
tions increased HRQoL. However, this improvement was not 
independent of changes in depression, indicating that the effect 
of lurasidone on improving patient HRQoL may act through a re-
duction in depressive symptoms associated with BD. Similarly, 
Gonda and colleagues (2016) found that patients enhanced both 
their work functional outcome and QoL after receiving prophy-
lactic lamotrigine therapy at 6-months follow-up. In young 
patients (10–17 years old) with an acute episode of bipolar de-
pression, it was found that those who received olanzapine/
fluoxetine combination presented better QoL scores compared 
with those receiving placebo (Walker et al., 2017).
Psychological Interventions
Even though physical activity is not a psychological interven-
tion itself, it is well-known for increasing well-being and QoL; 
however, the impact of this kind of interventions has been less 
studied in the field of BD. Vancampfort and colleagues (2017) 
proved the effect of 150  min/wk of physical activity on phys-
ical, psychological, social, and environmental QoL; those pa-
tients who did not meet the established minimum (150 minutes) 
showed lower QoL outcomes.
Involving the family, O’Donnell and colleagues (2017) tested 
the effect of 2 psychological interventions on QoL scores in a 
sample of adolescents with BD. They compared the efficacy of a 
FFTplus pharmacotherapy vs brief psychoeducation plus pharma-
cotherapy on self-related QoL over 2  years. They found the 2 
groups did not differ in overall QoL scores at 24 months follow-up. 
However, adolescents who received the FFT had greater improve-
ments in quality of family relationships and physical well-being 
compared with the brief psychoeducation program. Besides, 
internet-based approaches using smartphones are gaining trac-
tion (Lauder et al., 2015; Hidalgo-Mazzei et al., 2018), representing 
a useful and attractive tool especially for the young population 
with BD (Bauer et al., 2018). So far, some preliminary studies using 
a mobile application (SIMPLe) have reported an improvement of 
biological rhythms (Hidalgo-Mazzei et  al., 2017) and increased 
QoL and well-being (Hidalgo-Mazzei et al., 2018).
There is much room for improvement in the field of sub-
jective well-being and QoL. These above-mentioned inter-
ventions may shed some light regarding the path to follow. 
Nevertheless, it is important to keep in mind that those patients 
who suffer from more depressive symptoms, irritability, and 
psychiatric comorbid conditions present lower QoL and func-
tional outcomes (IsHak et al., 2012; Sylvia et al., 2017); hence, 
all the strategies directed to reduce medical and psychiatric 
burdens might also be useful to increase patients’ well-being 
and QoL. It is also worth mentioning that some authors defend 
that QoL depends not only on clinical remission but also re-
lies on functional recovery (Vieta and Torrent, 2016). In this line, 
poor QoL is also associated with poor occupational outcome, re-
duced academic attainment (Marwaha et al., 2013), and difficul-
ties in activities of daily life (Träger et al., 2017). Future studies 
should include subjective measures (such as QoL, well-being) to 
better understand the relationship with these clinical variables. 
Figure 2 represents a brief summary of the therapies and strat-
egies that have been presented in this review.
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Figure 2. Overview of proven and promising therapies to treat bipolar disorder. CBT, cognitive behavioral therapy; EMDR, Eye Movement Desensitization and Repro-
cessing; EPO, erythropoietin; FFT, family-focused treatment; IPSRT, Interpersonal and Social Rhythm Therapy; IRRI, Integrated Risk Reduction Intervention; NEW tx, 
nutrition, exercise and wellness treatment; QoL, quality of life. 
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Conclusions
Because the construct of psychosocial functioning is complex 
and difficult to measure, it is therefore recommended to assess 
it based on the combination of 3 different approaches: (1) a sub-
jective assessment that involves a self-administered measure 
(SDS, WHODAS 2.0, etc.), (2) a semi-objective measure including 
an interviewer-rated assessment (FAST, LIFE-RIFT, GAF, etc.), 
and (3) an objective assessment based on performance-based 
measurements (i.e., UPSA). Taking into account these different 
approaches might help to better disentangle the variables as-
sociated with the functional outcomes in BD, which are often 
heterogeneous and influenced by demographic, clinical, and 
neurocognitive factors.
Regardless of the great variability in the assessment of psy-
chosocial functioning, many efforts have successfully improved 
functional outcomes in BD. But where are we now? At the 
present moment, the interventions that have proven to be ef-
fective at enhancing functioning and/or QoL include lurasidone, 
lamotrigine, FR, some programs of cognitive remediation, ISPRT, 
FFT, and NEW tx, among others. These therapies have set the 
stage for developing further interventions to prevent func-
tional decline and ensure well-being, because this is where we 
go. Ideally, future therapies should focus not only on restoring 
functional outcomes but also preventing functional decline and 
enhancing QoL and well-being. In this regard, those programs 
that target cognitive enhancement and promote healthy life-
styles (including healthy nutrition patterns and physical ac-
tivity) are urgently needed, since they constitute a preventive 
tool for cognitive and functional decline. Although more studies 
are still needed, multicomponent therapies might be also a good 
option since they include different approaches to cover several 
areas at a time (symptoms, functioning, cognition, well-being, 
etc.). Finally, it is likely that the future will also include person-
alized treatments focusing on tailored interventions that may 
differ from one patient to another (Salagre et al., 2018); in this 
sense, the type and duration of interventions might differ from 
patients recently diagnosed and patients with a complex course 
of the illness who might take advantage of restorative therapies 
such as cognitive and FR (Solé et al., 2017).
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